From the Journals

Study finds sharp drop in opioid scripts among most specialties


 

What’s missing

Maya Hambright, MD, a family medicine physician in New York’s Hudson Valley, who has been working mainly in addiction in response to the opioid overdose crisis, observed that the drop in total prescribed volume of prescription painkillers does not necessarily translate into a reduction in use of opioids

“No one is taking fewer opioids,” Dr. Hambright told this news organization. “I can say that comfortably. They are just getting them from other sources.”

CDC data support Dr. Hambright’s view.

An estimated 100,306 people in the United States died of a drug overdose in the 12 months that ended in April 2021, an increase of 28.5% from the 78,056 deaths during the same period the year before, according to the CDC.

Dr. Hambright said more physicians need to be involved in prescribing medication-assisted treatment (MAT).

The federal government has in the past year loosened restrictions on a requirement, known as an X waiver. Certain clinicians have been exempted from training requirements, as explained in the frequently asked questions page on the Substance Abuse and Mental Health Services Administration website.

SAMHSA says legislation is required to eliminate the waiver. As of Dec. 30, 2021, more than half of the members of the U.S. House of Representatives were listed as sponsors of the Mainstreaming Addiction Treatment (MAT) Act (HR 1384), which would end the need for X waivers. The bill has the backing of 187 Democrats and 43 Republicans.

At this time, too many physicians shy away from offering MAT, Dr. Hambright said.

“People are still scared of it,” she said. “People don’t want to deal with addicts.”

But Dr. Hambright said it’s well worth the initial time invested in having the needed conversations with patients about MAT.

“Afterwards, it’s so straightforward. People feel better. They’re healthier. It’s amazing,” she said. “You’re changing lives.”

The research was supported by grants from the National Institutes of Health. Dr. Stein and coauthors reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Tough pain relief choices in the COVID-19 pandemic
MDedge Cardiology
How to convince patients muscle pain isn’t a statin Achilles heel: StatinWISE
MDedge Cardiology
Hypertension worsened by commonly used prescription meds
MDedge Cardiology
NSAIDs don’t make COVID-19 worse in hospitalized patients
MDedge Cardiology
FDA OKs spinal cord stimulation for diabetic neuropathy pain
MDedge Cardiology
Pandemic derails small success in lowering diabetes-related amputations
MDedge Cardiology
Growing proportion of cardiac arrests in U.S. considered opioid related
MDedge Cardiology
Case: Patient with statin-associated muscle symptoms
MDedge Cardiology
Most muscle pain on statins not a drug effect: SAMSON in print
MDedge Cardiology
Califf plans work on opioids, accelerated approvals on return to FDA
MDedge Cardiology